The June 2025 issue of the Journal of Drugs in Dermatology delivers a diverse and thought-provoking selection of studies that place a spotlight on acne and rosacea while spanning the latest innovations and clinical insights across the dermatology spectrum. This month’s editor’s picks feature new approaches to some of the field’s most common—and challenging—conditions, from acne-induced macular hyperpigmentation in patients with highly melanated skin, to advances in gentle-yet-effective acne care, and exciting developments in the treatment of periorificial dermatitis and atopic dermatitis.
In addition focusing on acne and rosacea, the June issue also highlights breakthroughs in hyperpigmentation management, novel therapies for psoriasis and seborrheic dermatitis, and new considerations for safe and effective isotretinoin use. Dive into expert-driven algorithms, emerging topical treatments, and the expanding potential of CGRP and PDE4 inhibitors.
Whether you’re seeking the latest evidence for clinical decision-making or eager to stay ahead of therapeutic trends, this edition offers practical pearls and innovative research to help elevate patient care. Here are our top picks from the June issue:
Treatment of Acne-Induced Macular Hyperpigmentation in Fitzpatrick Skin Types V to VI: A Scoping Review highlights the urgent need for more inclusive clinical research and tailored treatment strategies for AMH in patients with highly melanated skin.
Novel 2% Salicylic Acid Cleanser With Polymeric Cleansing Technology Treats Acne Without Compromising Skin Barrier demonstrates the efficacy of the new SA-PCT cleanser in improving acne-prone skin while maintaining the skin barrier.
Clinical Profile of Halobetasol Propionate 0.01%/ Tazarotene 0.045% Lotion in Patients With Hyperkeratotic Plaque Psoriasis discusses how HP/TAZ is an efficacious and well-tolerated treatment for hyperkeratotic psoriatic plaques
Rapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic Dermatitis shares howshares the results of this 813-patient trial.
Thiamidol: A Breakthrough Innovation in the Treatment of Hyperpigmentation describes the current pre-clinical and clinical safety and efficacy data of Thiamidol formulations aimed at educating the dermatology community.
A Single-Center Pilot Study to Evaluate the Efficacy, Safety, and Tolerability of Sarecycline for Treating Periorificial Dermatitis discusses exploratory results and expresses the need for more large-scale clinical studies evaluating treatment options for POD.
Practical Algorithm on Topical Treatment of Flaring Atopic Dermatitis (AD) With or Without Secondary Infection presents findings from a face-to-face meeting of an expert panel to develop a practice-based algorithm for managing AD flares.
PDE4 Inhibitors: Bridging Molecular Insights With Clinical Impact supports dermatology clinicians in selecting targeted therapies that improve patient outcomes, adherence, and quality of life.
Need for Speed: Topical Roflumilast for Rapid Control of Seborrheic Dermatitis Flares suggests that topical roflumilast may work even faster than topical corticosteroids in controlling flares.
Considerations on Concurrent Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Isotretinoin advocates for continued study and vigilance when initiating isotretinoin in patients on GLP1-RAs.
Weight Change and Dose Adjustment in Isotretinoin Therapy: A Retrospective Study investigates isotretinoin therapy on adolescent patients.
Exploring the Potential Dermatological Benefits of CGRP Inhibition: A Case Report contributes to the growing body of evidence suggesting that CGRP inhibitors could offer benefits beyond migraine treatment.
Find more JDD Issue Highlights here.
